GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opus Genetics Inc (NAS:IRD) » Definitions » Asset Turnover

IRD (Opus Genetics) Asset Turnover : 0.09 (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Opus Genetics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Opus Genetics's Revenue for the three months ended in Sep. 2024 was $3.87 Mil. Opus Genetics's Total Assets for the quarter that ended in Sep. 2024 was $42.61 Mil. Therefore, Opus Genetics's Asset Turnover for the quarter that ended in Sep. 2024 was 0.09.

Asset Turnover is linked to ROE % through Du Pont Formula. Opus Genetics's annualized ROE % for the quarter that ended in Sep. 2024 was -80.35%. It is also linked to ROA % through Du Pont Formula. Opus Genetics's annualized ROA % for the quarter that ended in Sep. 2024 was -70.65%.


Opus Genetics Asset Turnover Historical Data

The historical data trend for Opus Genetics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opus Genetics Asset Turnover Chart

Opus Genetics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
- - 0.03 1.06 0.37

Opus Genetics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.03 0.03 0.02 0.09

Competitive Comparison of Opus Genetics's Asset Turnover

For the Biotechnology subindustry, Opus Genetics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Opus Genetics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opus Genetics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Opus Genetics's Asset Turnover falls into.



Opus Genetics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Opus Genetics's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=19.049/( (48.992+53.948)/ 2 )
=19.049/51.47
=0.37

Opus Genetics's Asset Turnover for the quarter that ended in Sep. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=3.867/( (44.834+40.389)/ 2 )
=3.867/42.6115
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Opus Genetics  (NAS:IRD) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Opus Genetics's annulized ROE % for the quarter that ended in Sep. 2024 is

ROE %**(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-30.104/37.468
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-30.104 / 15.468)*(15.468 / 42.6115)*(42.6115/ 37.468)
=Net Margin %*Asset Turnover*Equity Multiplier
=-194.62 %*0.363*1.1373
=ROA %*Equity Multiplier
=-70.65 %*1.1373
=-80.35 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Opus Genetics's annulized ROA % for the quarter that ended in Sep. 2024 is

ROA %(Q: Sep. 2024 )
=Net Income/Total Assets
=-30.104/42.6115
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-30.104 / 15.468)*(15.468 / 42.6115)
=Net Margin %*Asset Turnover
=-194.62 %*0.363
=-70.65 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Opus Genetics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Opus Genetics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Opus Genetics Business Description

Traded in Other Exchanges
Address
37000 Grand River Avenue, Suite 120, Farmington Hills, MI, USA, 48335
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Executives
George Magrath officer: Chief Executive Officer 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Ronil A. Patel officer: SVP, Operations & Bus. Dev. 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Mina Sooch director, officer: President and CEO 17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152
Manuso James S J director 5130 ROUTE 212, WILLOW NY 12495
Jay Pepose director 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Susan Benton director 3916 VALRICO GROVE DRIVE, VALRICO FL 33594
Rabourn Amy Zaremba officer: VP of Finance 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Cam Gallagher director 6042 CORNERSTONE CT. WEST, SUITE B, SAN DIEGO CA 92121
Alan R Meyer director
Sean Ainsworth director 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Bernhard Hoffmann officer: VP of Corp. Dev. & Ops & Sec. 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Lara Sullivan director C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850
Ben Gil Price director 8297 CHAMPIONS GATE BLVD. #444, CHAMPIONS GATE FL 33896
Douglas J Swirsky officer: President and CFO C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Lisa Nolan officer: Chief Business Officer 36 ROCKLAND MILLS, ROCKLAND DE 19732